Document Classification

Section Type: RESULTS

Text: Patients who received zoledronic acid had stable BMD at 36 months (lumbar spine +0. 4 %, mean difference 0. 004 g/cm (2) [-0. 024 to 0. 032] ; trochanter +0. 8 %, mean difference 0. 006 g/cm (2) [-0. 018 to 0. 028]) and increased BMD at 60 months at both sites (lumbar spine +4. 0 %, mean difference 0. 039 g/cm (2) [0. 005-0. 075], p = 0. 02 ; trochanter +3. 9 %, mean difference 0. 028 g/cm (2) [0. 003-0. 058], p = 0. 07) compared with baseline.